Don't be too Quick to Jump on the Jardiance (empagliflozin) Bandwagon

You'll hear cautious optimism about cardiovascular benefits with the SGLT2 inhibitor, empagliflozin (Jardiance).

Until now, metformin seemed to be the only diabetes med linked to a reduction in cardiovascular events in patients with type 2 diabetes.

But new evidence suggests empagliflozin also reduces CV risk.